Inhibikase Therapeutics, Inc. (IKT)
NASDAQ·Healthcare·Biotechnology
$1.53
+1.67%
Mkt Cap $200.93M
Analyst Ratings
No recent rating data.
Price Target (6 analysts)
$4.83
Range $1.50 – $8.00
Implied Upside
+216.7%
Consensus $4.83 vs current $1.53
NASDAQ·Healthcare·Biotechnology
$1.53
+1.67%
Mkt Cap $200.93M
No recent rating data.
Price Target (6 analysts)
$4.83
Range $1.50 – $8.00
+216.7%
Consensus $4.83 vs current $1.53